全文获取类型
收费全文 | 44945篇 |
免费 | 2968篇 |
国内免费 | 742篇 |
专业分类
耳鼻咽喉 | 248篇 |
儿科学 | 1442篇 |
妇产科学 | 298篇 |
基础医学 | 3808篇 |
口腔科学 | 299篇 |
临床医学 | 5421篇 |
内科学 | 12381篇 |
皮肤病学 | 270篇 |
神经病学 | 1483篇 |
特种医学 | 2550篇 |
外科学 | 5002篇 |
综合类 | 6671篇 |
现状与发展 | 2篇 |
预防医学 | 2715篇 |
眼科学 | 822篇 |
药学 | 2922篇 |
26篇 | |
中国医学 | 1366篇 |
肿瘤学 | 929篇 |
出版年
2024年 | 41篇 |
2023年 | 731篇 |
2022年 | 1281篇 |
2021年 | 2009篇 |
2020年 | 1886篇 |
2019年 | 1705篇 |
2018年 | 1677篇 |
2017年 | 1430篇 |
2016年 | 1421篇 |
2015年 | 1551篇 |
2014年 | 3108篇 |
2013年 | 2854篇 |
2012年 | 2516篇 |
2011年 | 2719篇 |
2010年 | 2170篇 |
2009年 | 2196篇 |
2008年 | 2105篇 |
2007年 | 2162篇 |
2006年 | 2001篇 |
2005年 | 1722篇 |
2004年 | 1337篇 |
2003年 | 1166篇 |
2002年 | 925篇 |
2001年 | 927篇 |
2000年 | 767篇 |
1999年 | 679篇 |
1998年 | 560篇 |
1997年 | 518篇 |
1996年 | 420篇 |
1995年 | 473篇 |
1994年 | 424篇 |
1993年 | 344篇 |
1992年 | 309篇 |
1991年 | 274篇 |
1990年 | 255篇 |
1989年 | 239篇 |
1988年 | 198篇 |
1987年 | 201篇 |
1986年 | 168篇 |
1985年 | 212篇 |
1984年 | 185篇 |
1983年 | 87篇 |
1982年 | 138篇 |
1981年 | 122篇 |
1980年 | 100篇 |
1979年 | 85篇 |
1978年 | 72篇 |
1977年 | 53篇 |
1976年 | 41篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Revista portuguesa de cardiologia》2022,41(9):783-789
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation. 相似文献
3.
《Journal of Cardiovascular Computed Tomography》2022,16(6):517-523
BackgroundSelection of the transcatheter heart valve size for a mitral valve-in-valve procedure is based on the type and manufacturer’s labelled size. However, accurate information of surgical heart valve (SHV) size may not be available in the patient’s medical record. The purpose of this study is to establish reference data for computed tomography (CT) dimensions of commonly used mitral SHV in order to determine the manufacturer’s labelled size from a cardiac CT data set.MethodsCT datasets of 105 patients with surgical mitral bioprosthesis and available manufacturer labeled datasets were included in the analysis. CT derived valve dimensions were assessed by two observers using multiplanar reformats aligned with the basal sewing ring. A circular region of interest was used in a standardized fashion to minimize influence of image acquisition and reconstruction parameters. Interobserver variability was assessed by Bland-Altman analysis.ResultsThe CT-derived dimensions were stratified by valve size and type, and SHV properties were demonstrated for 5 common valve types. Variability of measurements was small and inter-observer limits of agreement were narrow. Stratified by SHV type, no overlap was noted for CT-derived dimensions among different SHV sizes . A reference table of CT characteristics of surgical mitral bioprosthesis types was created.ConclusionThe study provides reference CT data for determining the manufacturers’ labeled SHV size across a range of commonly used mitral SHVs. The findings will be important to help identify types of surgical mitral bioprosthesis utilizing CT characteristics for patients without SHV size documentation. 相似文献
4.
《Obstetrics, Gynaecology and Reproductive Medicine》2022,32(8):179-187
Continuous utero-placental circulation, and patent umbilical blood vessels ensure an uninterrupted transfer of oxygen and nutrients to the fetus as well as clearance of metabolic waste products. The onset of labour characterized by progressive and strong uterine contractions poses a threat to fetal oxygenation as a result of collapsing the spiral arterioles traversing the myometrium to supply the placental bed, and repetitive compression of the blood vessels within the umbilical cord. Human fetuses are equipped with compensatory mechanisms to cope with transient interruptions of blood supply during labour. The ability to compensate may be blunted in cases of poor fetal reserves, increased metabolic demand (macrosomia or maternal fever), and due to non-hypoxic pathways (e.g. chorioamniontis or fetal hypovolumia-hypotension syndrome). Intrapartum fetal surveillance involves prompt recognition of the features that signal the onset of fetal decompensation on the cardiotocograph (CTG) to ensure a timely intervention to avoid hypoxic-ischaemic encephalopathy (HIE) or perinatal deaths. This article summarises a ‘physiological approach’ to the interpretation of the CTG which, in places, conflicts with other current UK guidance. 相似文献
5.
6.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):591-604.e3
ObjectivesGuidelines suggest aortic valve replacement (AVR) for low-risk asymptomatic patients. Indications for transcatheter AVR now include low-risk patients, making it imperative to understand state-of-the-art surgical AVR (SAVR) in this population. Therefore, we compared SAVR outcomes in low-risk patients with those expected from Society of Thoracic Surgeons (STS) models and assessed their intermediate-term survival.MethodsFrom January 2005 to January 2017, 3493 isolated SAVRs were performed in 3474 patients with STS predicted risk of mortality <4%. Observed operative mortality and composite major morbidity or mortality were compared with STS-expected outcomes according to calendar year of surgery. Logistic regression analysis was used to identify risk factors for these outcomes. Patients were followed for time-related mortality.ResultsWith 15 observed operative deaths (0.43%) compared with 55 expected (1.6%), the observed:expected ratio was 0.27 for mortality (95% confidence interval [CI], 0.14-0.42), stroke 0.65 (95% CI, 0.41-0.89), and reoperation 0.50 (95% CI, 0.42-0.60). Major morbidity or mortality steadily declined, with probabilities of 8.6%, 6.7%, and 5.2% in 2006, 2011, and 2016, respectively, while STS-expected risk remained at approximately 12%. Mitral valve regurgitation, ventricular hypertrophy, pulmonary, renal, and hepatic failure, coronary artery disease, and earlier surgery date were residual risk factors. Survival was 98%, 91%, and 82% at 1, 5, and 9 years, respectively, superior to that predicted for the US age-race-sex–matched population.ConclusionsSTS risk models overestimate contemporary SAVR risk at a high-volume center, supporting efforts to create a more agile quality assessment program. SAVR in low-risk patients provides durable survival benefit, supporting early surgery and providing a benchmark for transcatheter AVR. 相似文献
7.
8.
9.
10.